Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study

ConclusionGalcanezumab was associated with statistically significant changes from baseline in the PRO measures across the entire 12-month treatment period. These results indicate improved health-related quality of life and decreased disability among patients treated with galcanezumab.
Source: Quality of Life Research - Category: Health Management Source Type: research